CorMedix, Inc. announced that it has signed a commercial agreement with MKM Co-Pharma GmbH. CorMedix entered into this agreement while awaiting the outcome of its application in the European Union for a CE mark for Neutrolin(R), a catheter lock solution. If approved for use in the EU, Neutrolin will be used for the prevention of catheter related bloodstream infection and maintenance of catheter patency in hemodialysis patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5 USD | +2.04% |
|
+16.28% | +32.98% |
07-03 | CorMedix Begins Outpatient Distribution of DefenCath | MT |
05-28 | CorMedix Shares Rise on Multiyear DefenCath Supply Deal | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.98% | 269M | |
+6.87% | 72.01B | |
+34.26% | 10.39B | |
+40.84% | 5.26B | |
-18.53% | 4.64B | |
+12.65% | 3.7B | |
+27.58% | 2.3B | |
-39.96% | 1.8B | |
-45.87% | 1.7B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- CRMD Stock
- News CorMedix Inc.
- CorMedix, Inc. Signs Sales and Marketing Agreement with MKM Co-Pharma GmbH